platinum has been researched along with Carcinoma, Large Cell in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Economidou, SC; Fotopoulos, G; Vrontis, K | 1 |
| Maeda, A; Nakata, M; Nojima, Y; Okita, R; Saisho, S; Shimizu, K; Yukawa, T | 1 |
| Eguchi, K; Ichinose, Y; Kishi, K; Minato, K; Nishikawa, M; Nogami, N; Okamoto, H; Seki, N; Seto, T; Shinkai, T; Takiguchi, Y; Watanabe, K | 1 |
| Abedallaa, N; Baey, C; Besse, B; de Montpreville, VT; Fabre, D; Guigay, J; Pechoux, CL; Pignon, JP; Planchard, D; Soria, JC; Tremblay, L | 1 |
| Cohen, J; Halm, EA; Mandeli, J; Mhango, G; Sigel, K; Strauss, G; Wisnivesky, J | 1 |
1 trial(s) available for platinum and Carcinoma, Large Cell
| Article | Year |
|---|---|
Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Platinum; Salvage Therapy; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2011 |
4 other study(ies) available for platinum and Carcinoma, Large Cell
| Article | Year |
|---|---|
Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platinum; Prospective Studies; Retrospective Studies; Small Cell Lung Carcinoma; Survival Analysis; Treatment Outcome | 2022 |
Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cyclooxygenase 2; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2015 |
Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cyclophosphamide; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Lymph Nodes; Male; Methotrexate; Middle Aged; Neoplasm Staging; Perioperative Care; Platinum; Pneumonectomy; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Outcomes after adjuvant platinum-based chemotherapy in elderly NSCLC patients with T4 disease.
Topics: Adenocarcinoma; Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; SEER Program; Survival Rate | 2013 |